Skip to content

Released Nov 14, 2024, before the open

10-Q filed Nov 14, 2024, 45 days after period end · 0001558370-24-015612

Q3 2024 · 10-Q
Revenue$17.96M+73.6% vs Q3 2023+33.3% vs Q2 2024
Net Income$3.24MN/M vs Q3 2023N/M vs Q2 2024
EPS Diluted$0.03N/M vs Q3 2023N/M vs Q2 2024
Operating Income$3,991,000N/M
Operating Cash Flowderived$4,105,000N/M
Free Cash Flowderived$4,018,000N/M
Margins · derived
Operating margin22.2%+40.5 pt vs Q3 2023
Net margin18.0%+35.9 pt vs Q3 2023

What the release said

The release

Same quarter

MetricQ3 2024Q3 2023Q3 2022Q3 2021
Revenue$17.96M$10.35M$14.18M$12.05M
Net Income$3.24M-$1.85M-$3.57M-$4.20M
EPS Diluted$0.03-$0.04-$0.07-$0.09

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR